Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA | BSE: 524715

Expensive Performer

Download real time

1747.40 2.50 (0.14%)

26.88% Gain from 52W Low

986.9K NSE+BSE Volume

NSE 22 Apr, 2025 3:31 PM (IST)

6

Broker 1Year buys

6 active buys

0

Broker 1Year sells

0 active sells

2

Broker 1Year neutral

2 active holds

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average target of 2054. The consensus estimate represents an upside of 17.55% from the last price of 1747.40. View 21 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	23 Apr 2025	Sun Pharmaceutical	Consensus Share Price Target	1747.40	2047.89	-	17.20	buy	pdf Detailed Estimates
	10 Apr 2025	Sun Pharmaceutical	Emkay	1747.40	2400.00	1652.20 (5.76%)	37.35	Buy	pdf post cache		Broker Report Order vacating injunction on Leqselvi a material positive Emkay The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24. pdf Copy Link Share on Share on Share on Share on Alert
	11 Mar 2025	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1747.40	1895.00	1655.30 (5.56%)	8.45	Buy	pdf post cache		Broker Report On a spree to expand specialty portfolio ICICI Securities Limited Sun Pharma (Sun) is acquiring US-based early-stage oncology-focused biotech company Checkpoint Therapeutics (Checkpoint) for an upfront cash payment of USD 4.1/share (total outgo of USD 355mn) and USD 0.7/share in cash in future milestones. pdf Copy Link Share on Share on Share on Share on Alert
	10 Mar 2025	Sun Pharmaceutical	BOB Capital Markets Ltd.	1747.40	2086.00	1611.50 (8.43%)	19.38	Buy	pdf post cache		Broker Report Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio BOB Capital Markets Ltd. SUNP to acquire Checkpoint Therapeutic for US$ 4.10 a share, at ~66% premium to its last closing price. Deal valued at US$ 355mn pdf Copy Link Share on Share on Share on Share on Alert
	04 Feb 2025	Sun Pharmaceutical	KRChoksey	1747.40	1967.00	1765.25 (-1.01%)	12.57	Accumulate	pdf post cache		Broker Report Specialty drugs and new product launches to drive growth KRChoksey Sun Pharma’s revenue was largely in-line with our estimates. However, EBITDA beat our estimates (+4.7%) due to lower-than-expected operating expenses and Adj. PAT beat our estimates due to better operating performance and better than expected other income. pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2025	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1747.40	2086.00	1742.20 (0.30%)	19.38	Buy	pdf post cache		Broker Report Sun Pharma (BUY): Strong performance to continue BOB Capital Markets Ltd. Domestic sales grew by 14% in Q3FY25 driven partially by volume/new launches and price hikes. Strong domestic sales growth to continue pdf Copy Link Share on Share on Share on Share on Alert
	21 Jan 2025	Sun Pharmaceutical	Emkay Target	1747.40	2400.00	1762.70 (-0.87%)	37.35	Buy	pdf post cache		Broker Report Addressing the oral IL-23 antagonist challenge to Ilumya Emkay J&J, in a recent investor interaction, had stated that its oral IL-23 receptor antagonist peptide (Icotrokinra) could potentially compete with existing oral as well as injectable treatment options for moderate to severe plaque psoriasis. pdf Copy Link Share on Share on Share on Share on Alert
	30 Oct 2024	Sun Pharmaceutical	KRChoksey Target	1747.40	1967.00	1852.10 (-5.65%)	12.57	Accumulate	pdf post cache		Broker Report US Specialty and domestic business aid strong performance KRChoksey Sun Pharma revenue came in-line with our estimates (-1.0%) whereas EBITDA was largely in-line with our estimate (-2.1%) and Adj. PAT missed our estimate due to higher-than-expected finance costs and lower-than-expected other income. pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Sun Pharmaceutical	ICICI Direct Reco Target	1747.40	2185.00	1871.60 (-6.64%)	25.04	Buy	pdf post cache		Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1747.40	2019.00	1871.60 (-6.64%)	15.54	Hold	pdf post cache		Broker Report Sun Pharma (HOLD): All positives built into current valuations BOB Capital Markets Ltd. SUNP reported 11% domestic sales growth led by 5% volume growth from ~14,000 MRs; leads in Rx count across 13 doctor categories pdf Copy Link Share on Share on Share on Share on Alert
	28 Oct 2024	Sun Pharmaceutical	Sharekhan Target	1747.40	2264.00	1902.90 (-8.17%)	29.56	Buy	pdf post cache		Broker Report Company surpasses expectations across multiple metrics Sharekhan Sun Pharmaceutical Industries reported a revenue of ?13,291 crore for the quarter, reflecting a 9% year-over-year increase and a 5% rise quarter-over-quarter. This figure surpassed our estimates by 2%, despite experiencing price reductions in Taro’s portfolio and in Japan. pdf Copy Link Share on Share on Share on Share on Alert
	13 Aug 2024	Sun Pharmaceutical	KRChoksey Reco	1747.40	1827.00	1740.10 (0.42%)	Target met	Accumulate	pdf post cache		Broker Report Global Specialty and IPM growth to continue to drive growth KRChoksey SUNPHARMA exceeded our profitability estimates by a huge margin for Q1FY25. The EBITDA exceeded by 12% and EBITDA margins by 391 bps from our estimates while GPMs exceeded the expectations marginally by 36 bps from our estimates for Q1FY25. pdf Copy Link Share on Share on Share on Share on Alert
	02 Aug 2024	Sun Pharmaceutical	ICICI Direct Target	1747.40	1845.00	1731.65 (0.91%)	Target met	Hold	pdf post cache		Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	01 Aug 2024	Sun Pharmaceutical	Motilal Oswal Target	1747.40	1980.00	1715.20 (1.88%)	13.31	Buy	pdf post cache		Broker Report Specialty/DF drive earnings Motilal Oswal Sun Pharma (SUNP) delivered better-than-expected 1QFY25 earnings, led by an improved segmental mix and lower RM costs. pdf Copy Link Share on Share on Share on Share on Alert
	20 Jun 2024	Sun Pharmaceutical	Sharekhan Target	1747.40	1800.00	1471.00 (18.79%)	Target met	Buy	pdf post cache		Broker Report Dadra facility receiving WL to have no impact on the company’s financials Sharekhan Sun Pharma’s Dadra facility received a Warning Letter for a violation of cGMP regulations, which had previously received an Official Action Indicated (OAI) status on 11th Apr’24. pdf Copy Link Share on Share on Share on Share on Alert
	10 Jun 2024	Sun Pharmaceutical	Geojit BNP Paribas Reco Target	1747.40	1655.00	1513.10 (15.48%)	Target met	Hold	pdf post cache		Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1747.40	1530.00	1495.10 (16.88%)	Target met	Hold	pdf post cache		Broker Report Sun Pharma (HOLD): Gearing for higher R&D spend BOB Capital Markets Ltd. SUNP missed consensus EBITDA estimate by 4% as higher R&D spend offset gross margin gains; higher other income & low tax aided PAT pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Sun Pharmaceutical	ICICI Securities Limited Target	1747.40	1463.00	1495.10 (16.88%)	Target met	Hold	pdf post cache		Broker Report Steady quarter, valuation quite pricey ICICI Securities Limited Sun Pharma (Sun)’s Q4FY24 results were aided by higher other income, barring which, performance was marginally below our expectations. pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Sun Pharmaceutical	KRChoksey	1747.40	1827.00	1495.10 (16.88%)	Target met	Buy	pdf post cache		Broker Report Global Specialty and IPM growth to continue to drive growth KRChoksey Global specialty grew at 11.1% Y-o-Y (-8.7% Q-o-Q) to USD 271 Mn (19.1% of revenue) driven by ILLUMYA, Cequa, WINLEVI, and Odomzo in Q4FY24. It can be noted that large part of the global specialty sales accrue in the US. pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Sun Pharmaceutical	ICICI Direct Reco Target	1747.40	1530.00	1495.10 (16.88%)	Target met	Hold	pdf post cache		Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2024	Sun Pharmaceutical	Motilal Oswal Target	1747.40	1810.00	1539.30 (13.52%)	Target met	Buy	pdf post cache		Broker Report The US and India businesses drive earnings growth Motilal Oswal Sun Pharma (SUNP) reported a slight miss at the operational level for 4QFY24. This was due to lower-than-expected sales in the ROW market and higher-than-expected opex for the quarter. pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners